The entire cohort had a 31.0% overall response rate; nonetheless, a 46.4% response rate for patients with PD-L1 expressing tumor cells was observed in contrast to 22% for PD-L1 negative carcinomas. This evidence concerns the gene CD274 and neoplasm.